



IMAGE

Infographic: Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation in patients with proliferative diabetic retinopathy (PDR): the CLARITY study

Imran H. Yusuf ^{1,2}, Christin Henein ^{3,4} and Sobha Sivaprasad ⁴

© The Author(s), under exclusive licence to The Royal College of Ophthalmologists 2023


Eye (2024) 38:26–27; <https://doi.org/10.1038/s41433-023-02391-5>

Mean BCVA at baseline was 81.9 letters in the PRP group and 80.9 letters in the aflibercept group. Visual outcomes are presented as the adjusted difference between groups, accounting for baseline differences in BCVA. There were no reported cases of endophthalmitis in either group. PDR – proliferative diabetic retinopathy; PRP – panretinal photocoagulation; DM – diabetes mellitus; VEGF – vascular endothelial growth factor; CRT – central retinal thickness; PRN – pro re nata (i.e. as needed); BCVA – best corrected visual acuity; ETDRS – early treatment diabetic retinopathy study; CI – confidence interval; adj. – adjusted.

Reference: Sivaprasad et al. “Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial.” *Lancet*, 2017 Jun 3;389(10085):2193–2203.

FUNDING

Medical Research Council UK (MR/R000735/1).



¹Nuffield Laboratory of Ophthalmology, Department of Clinical Neurosciences, Oxford University, West Wing, John Radcliffe Hospital, Oxford OX3 9DU, UK. ²Oxford Eye Hospital, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Headley Way, Oxford OX3 9DU, UK. ³UCL Institute of Ophthalmology, 11-43 Bath Street, London EC1V 9EL, UK. ⁴NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, UK. [✉]email: Imran.yusuf@eye.ox.ac.uk

Received: 22 November 2022 Revised: 10 December 2022 Accepted: 13 January 2023
Published online: 21 April 2023

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Correspondence and requests for materials should be addressed to Imran H. Yusuf.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Please note that the infographic is best viewed online.